(19)
(11) EP 4 816 414 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 23959739.6

(22) Date of filing: 28.11.2023
(51) International Patent Classification (IPC): 
C07K 19/00(2006.01)
C12N 15/63(2006.01)
A61P 35/00(2006.01)
A61P 29/00(2006.01)
A61K 39/395(2006.01)
C12N 15/11(2006.01)
A61P 27/02(2006.01)
A61P 17/06(2006.01)
A61P 9/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 9/00; A61P 17/06; A61P 27/02; A61P 29/00; A61P 35/00; C07K 16/28; A61K 2039/505; C07K 2319/30; C07K 2317/76; C07K 2319/00; C07K 14/71
(86) International application number:
PCT/CN2023/134829
(87) International publication number:
WO 2025/111816 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(71) Applicant: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • SHEN, Wei Yong
    Beijing 100005 (CN)
  • ZHANG, Jinzhong
    Beijing 100005 (CN)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstraße 3
81675 München
81675 München (DE)

   


(54) MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC, INFLAMMATORY, AND/OR FIBROTIC FACTORS